About

Ingo Helbig, M.D., is an Associate Professor of Neurology at the University of Pennsylvania's Perelman School of Medicine, affiliated with the Department of Neurology and the Genomics and Computational Biology graduate group. His clinical expertise encompasses neurology, neurogenetics, epilepsy, and pediatric neurology. Helbig's research focuses on gene findings for epileptic encephalopathies, with a pivotal role in the discovery of genes such as GRIN2A, CHD2, KCNA2, HCN1, and DNM1. His work has contributed significantly to understanding the genetic basis of epilepsy, including gene discovery in familial epilepsies and the study of copy number variations in common epilepsies. Helbig is also the main author of the blog 'Beyond the Ion Channel,' which has become an authoritative source in neurogenetics with over 10,000 monthly views. He completed his M.D. at the University of Heidelberg in Germany in 2005 and is actively involved in advancing neurogenetic research and clinical practice.

Research topics

• Biology
• Medicine
• Genetics
• Neuroscience
• Computational biology
• Psychiatry
• Computer Science
• Internal medicine
• Pediatrics
• Artificial Intelligence
• Pathology
• Psychology
• Data science
• Engineering
• Cell biology
• Multimedia
• Engineering ethics
• Emergency medicine
• Bioinformatics
• Finance
• Intensive care medicine
• Business
• Family medicine
• Virology

Selected publications

• Paediatric cerebrospinal fluid immune profiling distinguishes paediatric-onset multiple sclerosis from other paediatric-onset acute neurological disorders

  EBioMedicine · 2026-01-01

  articleOpen access

  BACKGROUND: The cerebrospinal fluid (CSF) provides a unique glimpse into the central nervous system (CNS) compartment and offers insights into immune processes associated with both healthy immune surveillance as well as inflammatory disorders of the CNS. The latter include demyelinating disorders, such as multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), that warrant different therapeutic approaches yet are not always straightforward to distinguish on clinical and imaging grounds alone. METHODS: We established a comprehensive phenotypic landscape of the paediatric CSF immune compartment across a range of non-inflammatory and inflammatory neurological disorders, with a focus on better elucidating CNS-associated immune mechanisms potentially involved in, and discriminating between, paediatric-onset MS (MS) and other paediatric-onset suspected neuroimmune disorders, including MOGAD. FINDINGS: CSF from paediatric patients with non-inflammatory neurological disorders is primarily composed of non-activated CD4+ T cells, with few if any B cells present. CSF from paediatric patients with acquired inflammatory demyelinating disorders is characterised by increased numbers of B cells compared to CSF of both patients with other inflammatory or non-inflammatory conditions. Certain features, including particular increased frequencies of antibody-secreting cells (ASCs) and decreased frequencies of CD14+ myeloid cells, distinguish MS from MOGAD and other acquired demyelinating syndromes. INTERPRETATION: Increased CSF ASC frequencies and decreased CSF CD14+ myeloid cell frequencies help distinguish paediatric-onset MS from paediatric-onset MOGAD and other acquired demyelinating syndromes. Our findings provide insight into CNS-associated immune mechanisms that may be present early in the clinical course of MS. FUNDING: Stated in acknowledgements section of manuscript.

  PublisherDOI

• Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes

  Nature Genetics · 2026-04-01 · 2 citations

  articleOpen access

  Genetic variants in RNU4-2, which is transcribed into the U4 small nuclear RNA component of the major spliceosome, were recently shown to cause ReNU syndrome, a prevalent dominant neurodevelopmental disorder (NDD). These variants almost exclusively arise de novo and cluster within 18 nucleotides of RNU4-2. Here we describe a new recessive NDD associated with homozygous and compound heterozygous variants in RNU4-2. We identify 38 individuals with biallelic variants outside the 18-nucleotide ReNU syndrome region that cluster within other functionally important elements of U4: Stem II, the k-turn and the Sm protein binding site. We characterize the clinical phenotype in 31 individuals, demonstrating that the recessive disorder is clinically distinct from ReNU syndrome and is associated with distinctive white matter abnormalities, including enlarged perivascular spaces. Finally, we find reduced RNU4-2 transcript levels in individuals with the recessive disorder, suggesting a loss-of-function disease mechanism that is distinct from the mechanism underlying ReNU syndrome. Together, these findings expand the genotypic and phenotypic spectrum of RNU4-2-associated NDDs.

  PublisherOA PDFDOI

• Targeted long-read RNA sequencing for rare disease diagnosis and variant interpretation

  Science Advances · 2026-04-15

  articleOpen access

  Diagnosing rare genetic diseases remains a major challenge despite widespread clinical testing. Long-read RNA sequencing (RNA-seq) offers a powerful approach to capturing the effects of genetic variants on the transcriptome, yet challenges with sequencing coverage, cost, tissue selection, and scalability have limited its clinical adoption. To address this, we developed STRIPE (Sequencing Targeted RNAs Identifies Pathogenic Events), a targeted long-read RNA-seq-based strategy for rare disease diagnosis and variant interpretation. STRIPE enables deep sequencing of full-length transcripts for any customized disease-specific gene panel such that a wide range of clinically informative readouts, including transcript aberrations and sequence variants, can be detected at haplotype-level resolution. Applying STRIPE to 88 individuals spanning two major rare disease groups, we accurately reidentified known pathogenic variants and revealed their transcript consequences, including many unexpected ones. For 8 of 15 splice site region variants, we observed more complex RNA processing defects beyond single exon skipping or cryptic splice site activation. Notably, we find that donor splice site variants frequently activate cryptic intronic polyadenylation sites, leading to premature transcript termination. Leveraging unique strengths of long-read RNA-seq, STRIPE also resolved variants of uncertain significance and uncovered disease-causing variants in five previously undiagnosed individuals. Overall, STRIPE is a powerful, adaptable, and scalable strategy with broad potential to improve clinical variant interpretation and advance genetic diagnosis of rare diseases.

  PublisherDOI

• TRPM3-Associated Disorders: Clinical Spectrum and Treatment Options

  Neuropediatrics · 2025-09-26

  article
  PublisherDOI

• Characterization of the functional and clinical impacts of CACNA1A missense variants found in neurodevelopmental disorders

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-04-26

  preprintOpen access

  Abstract CACNA1A encodes the P/Q-type Ca V 2.1 calcium channels whose function underlies neuronal excitability, presynaptic neurotransmitter release, and Ca 2+ signaling in neurons. Pathogenic variants in CACNA1A have been found in individuals with various neurological conditions, including hemiplegic migraine, epilepsy, developmental delay, and ataxia. Clinical presentations can vary significantly between patients, with limited information known about the underlying neurobiology of these different clinical patterns. Adding further complication, prior work on pathogenic missense variants has demonstrated variable impacts on CaV2.1 channel function, sometimes in opposite directions. As such, the relationships between specific coding variants, electrophysiological properties, and clinical phenotypes remain elusive. In this study, we determined the biophysical properties of an allelic series of 42 de novo missense CACNA1A variants discovered in a neurodevelopmental disorder cohort of more than 31,000 individuals, together with the most common eight coding variants found in the general population. We found that all but one de novo variant altered at least one aspect of the channel properties examined, and the majority (70%) of the variants reduced the channel current density. In addition, for variants that encode human Ca V 2.1 channels (hCa V 2.1) with detectable currents, nearly 50% altered how channels respond to membrane potential, while common variations did not significantly change any channel biophysical properties. Coupled with our functional analyses and AlphaMissense prediction, we showed that Ca V 2.1 missense variants significantly underlie the risk of developmental epileptic encephalopathy. Subsequently, we examined the physiological impact of variant hCa V 2.1 using NEURON simulations as an omnibus output of neuronal function and found that abnormal biophysical channel properties have a profound impact on Purkinje cell excitability. Most interestingly, we correlated the clinical phenotype with molecular consequences of missense variants provided by our comprehensive functional analyses and found that distinct Ca V 2.1 channel molecular function is significantly associated with different clinical outcomes. By analyzing an entire allelic series of CACNA1A de novo changes in a large cohort of individuals with neurodevelopmental disorders, we provide a powerful approach to dissecting the role of missense variants in CACNA1A channelopathy, which in turn may help pave the way for future precision medicine initiatives.

  PublisherOA PDFDOI

• Reliability and Stability of Cerebral Palsy Classification Scales for Individuals with <i>STXBP1</i> Related Disorders and <i>SYNGAP1</i> Related Disorders

  medRxiv · 2025-11-06

  preprintOpen accessSenior author

  Abstract Aim To determine the interrater reliability and stability of the Gross Motor Function Classification System (GMFCS), mini–Manual Ability Classification System (mini-MACS), Manual Ability Classification System (MACS), and Communication Function Classification System (CFCS) in individuals with STXBP1 -Related Disorder ( STXBP1 -RD) and SYNGAP1 -Related Disorder ( SYNGAP1 -RD). Methods Data were collected from 83 individuals with STXBP1 -RD (mean age = 9.8 years) and 101 individuals with SYNGAP1 -RD (mean age = 10.9 years). Two raters completed the GMFCS, MACS/MiniMACS, and CFCS assessments on the same day, and test-retest stability was evaluated for participants with two longitudinal assessments. Results Interrater agreement varied from 73.8% to 77.3% for the STXBP1 -RD cohort and from 60.5% to 83.3% for the SYNGAP1 -RD cohort. Interrater reliability weighted kappa scores for the STXBP1 -RD cohort varied from 0.83 to 0.93 while the SYNGAP1 -RD cohort ranged from 0.66-0.81. Test-retest stability scores for the STXBP1 -RD group varied from 0.62 to 0.94 while the SYNGAP1 -RD group ranged from 0.38 to 0.78. Significant correlations were found between all assessment scales for both STXBP1 -RD (Kendall’s Tau range from 0.25-0.42) and SYNGAP1 -RD (Kendall’s Tau range from 0.19-0.45). Interpretation The GMFCS, MACS/MiniMACS, and CFCS demonstrate appropriate levels of interrater reliability and stability for individuals with STXBP1 -RD and SYNGAP1 -RD. What this paper adds Classification tools are reliable and stable in individuals with STXBP1 -RD and SYNGAP1 -RD. Gross motor function is least affected for both conditions. Language function is most affected for both conditions. Correlations are decreased compared to children with cerebral palsy due to phenotype differences.

  PublisherOA PDFDOI

• A clinical and genotype-phenotype analysis of MACF1 variants

  The American Journal of Human Genetics · 2025-09-08 · 1 citations

  articleOpen access
  PublisherOA PDFDOI

• Single-Gene Abnormalities

  Elsevier eBooks · 2025-06-02

  book-chapterSenior author
  PublisherDOI

• The genetic and phenotypic spectrum of <i>GABRB1</i> -related disorders

  Brain · 2025-06-05 · 3 citations

  articleOpen access

  Pathogenic variants in GABAA receptor subunit genes (GABR*) are important contributors to rare and common genetic epilepsies. Here, we present a comprehensive analysis of variants in GABRB1, which encodes the GABAA receptor β1 subunit, by revealing their functional implications, establishing genotype-phenotype correlations and evaluating treatment response. Clinical information on individuals carrying a GABRB1 variant was obtained through an international collaboration and literature review. Our cohort included 19 individuals (7 males, 12 females) from 15 families harbouring 13 different GABRB1 variants (11 missense, 1 indel, 1 stop). Functional analysis was performed using two-electrode voltage-clamp recordings in Xenopus laevis oocytes. For all 11 missense variants, α1β1γ2 GABAA receptors with a single mutant β1 subunit were used. Four missense variants were selected for further functional analysis using α5β1γ2 GABAA receptors with two mutant β1 subunits. Gain-of-function (GoF) effects, characterized by increased GABA-sensitivity, were observed for eight missense variants. Loss-of-function (LoF) effects were observed for one variant and no functional effects for two variants. Clinically, GoF variants were only observed in individuals with severe early-onset disease, including profound intellectual disability, hypotonia and early mortality. Additionally, cortical visual impairment, dysmorphisms and cortical atrophy were exclusive to this cohort. By integrating previously reported clinical data for variants in other GABR* genes, we validated that these features were associated with GoF variants more broadly. The only LoF variant was identified in a nuclear family with the relatively milder syndrome of genetic epilepsy with febrile seizures plus. Seizures were therapy-resistant in all individuals with GoF variants and a single individual with a LoF variant. The GABAergic anti-seizure medication (ASM) vigabatrin caused life-threatening side-effects in two individuals with GoF variants, while the sodium-channel blocker (SCB) lamotrigine exacerbated seizures in a single individual carrying a LoF variant. By integrating data from literature on all GABR* variants, we observed a potential dichotomy in treatment responses: GABAergic and broad-spectrum ASMs, such as valproate and levetiracetam, were more effective for individuals with LoF variants in GABR* genes, while SCBs showed greater benefit for GoF variants. Additionally, there is an increased risk of adverse effects of SCBs in LoF and vigabatrin in GoF variants. Our results highlight the importance of functional characterization of variants and clinical predictors in guiding treatment strategies for individuals with GABRB1 and other GABR* variants, although larger prospective studies are needed to confirm these observations.

  PublisherOA PDFDOI

• <i>USP25</i> in genetic generalized epilepsy: a gene under scrutiny

  Brain · 2025-10-25 · 1 citations

  article

  not available

  PublisherDOI

Recent grants

• Joint analysis of genomic and electronic medical record data to assess outcomes and drug response in pediatric epilepsies

  NIH · $963k · 2020–2025

Frequent coauthors

• Sarah Weckhuysen

  VIB-UAntwerp Center for Molecular Neurology

  237 shared

• Dennis Lal

  224 shared

• Yvonne G. Weber

  RWTH Aachen University

  209 shared

• Rikke S. Møller

  University of Southern Denmark

  205 shared

• Renzo Guerrini

  University of Florence

  184 shared

• Hiltrud Muhle

  Kiel University

  183 shared

• Sarah von Spiczak

  159 shared

• Holger Lerche

  University of Tübingen

  158 shared

Education

• M.D., Clinical Medical

  University of Heidelberg, Germany

  2005